{"title":"前列腺良性疾病Cochrane综述的快速优先级","authors":"Juan V. A. Franco, Jae H. Jung, Philipp Dahm","doi":"10.1002/cesm.12002","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Benign conditions of the prostate include benign prostatic enlargement and prostatitis, which constitute an important cause of morbidity in men.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>We aimed to generate a list of priority topics of interest to our external stakeholders within our editorial scope.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Following Cochrane's guidance, we developed a tiered approach for consulting internal and external stakeholders, including members from Urological societies. First, we analyzed our portfolio, including different impact measurements, to assess the need for updates. Then, following criteria related to the feasibility, novelty and relevance of prospective topics for evidence synthesis, we narrowed the list to a suite of titles for updates or new reviews.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Twelve editors provided initial feedback as to what the priorities were for updating existing reviews and for new reviews in our portfolio. The editors identified gaps in our portfolio, mainly covering new treatments for benign prostatic hyperplasia. Then we consulted external stakeholders obtaining 30 responses from 14 countries. These stakeholders provided additional information about the relative importance of existing topics and suggested new ones. We identified that many of the latter were already covered in our portfolio, highlighting gaps in their dissemination. Finally, we narrowed down four priority topics that the editorial group will take forward and two additional topics that might need other considerations before being commissioned.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Following Cochrane's guidance on priority setting, we identified topics relevant to our editors and external stakeholders by analysing our portfolio and two rounds of surveys. Moreover, we identified opportunities for disseminating existing reviews. Further evaluation is needed of the following up commissioning process for priority reviews.</p>\n </section>\n </div>","PeriodicalId":100286,"journal":{"name":"Cochrane Evidence Synthesis and Methods","volume":"1 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cesm.12002","citationCount":"0","resultStr":"{\"title\":\"Quick prioritization of Cochrane reviews on benign conditions of the prostate\",\"authors\":\"Juan V. A. Franco, Jae H. Jung, Philipp Dahm\",\"doi\":\"10.1002/cesm.12002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>Benign conditions of the prostate include benign prostatic enlargement and prostatitis, which constitute an important cause of morbidity in men.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>We aimed to generate a list of priority topics of interest to our external stakeholders within our editorial scope.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Following Cochrane's guidance, we developed a tiered approach for consulting internal and external stakeholders, including members from Urological societies. First, we analyzed our portfolio, including different impact measurements, to assess the need for updates. Then, following criteria related to the feasibility, novelty and relevance of prospective topics for evidence synthesis, we narrowed the list to a suite of titles for updates or new reviews.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Twelve editors provided initial feedback as to what the priorities were for updating existing reviews and for new reviews in our portfolio. The editors identified gaps in our portfolio, mainly covering new treatments for benign prostatic hyperplasia. Then we consulted external stakeholders obtaining 30 responses from 14 countries. These stakeholders provided additional information about the relative importance of existing topics and suggested new ones. We identified that many of the latter were already covered in our portfolio, highlighting gaps in their dissemination. Finally, we narrowed down four priority topics that the editorial group will take forward and two additional topics that might need other considerations before being commissioned.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Following Cochrane's guidance on priority setting, we identified topics relevant to our editors and external stakeholders by analysing our portfolio and two rounds of surveys. Moreover, we identified opportunities for disseminating existing reviews. Further evaluation is needed of the following up commissioning process for priority reviews.</p>\\n </section>\\n </div>\",\"PeriodicalId\":100286,\"journal\":{\"name\":\"Cochrane Evidence Synthesis and Methods\",\"volume\":\"1 2\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-03-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cesm.12002\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cochrane Evidence Synthesis and Methods\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cesm.12002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cochrane Evidence Synthesis and Methods","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cesm.12002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Quick prioritization of Cochrane reviews on benign conditions of the prostate
Introduction
Benign conditions of the prostate include benign prostatic enlargement and prostatitis, which constitute an important cause of morbidity in men.
Objective
We aimed to generate a list of priority topics of interest to our external stakeholders within our editorial scope.
Methods
Following Cochrane's guidance, we developed a tiered approach for consulting internal and external stakeholders, including members from Urological societies. First, we analyzed our portfolio, including different impact measurements, to assess the need for updates. Then, following criteria related to the feasibility, novelty and relevance of prospective topics for evidence synthesis, we narrowed the list to a suite of titles for updates or new reviews.
Results
Twelve editors provided initial feedback as to what the priorities were for updating existing reviews and for new reviews in our portfolio. The editors identified gaps in our portfolio, mainly covering new treatments for benign prostatic hyperplasia. Then we consulted external stakeholders obtaining 30 responses from 14 countries. These stakeholders provided additional information about the relative importance of existing topics and suggested new ones. We identified that many of the latter were already covered in our portfolio, highlighting gaps in their dissemination. Finally, we narrowed down four priority topics that the editorial group will take forward and two additional topics that might need other considerations before being commissioned.
Conclusions
Following Cochrane's guidance on priority setting, we identified topics relevant to our editors and external stakeholders by analysing our portfolio and two rounds of surveys. Moreover, we identified opportunities for disseminating existing reviews. Further evaluation is needed of the following up commissioning process for priority reviews.